NCT06519097View on ClinicalTrials.gov

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2029

Conditions
Neoplasm of PancreasIPMN, Pancreatic
Interventions
DRUG

Vitamin E Delta Tocotrienol

"Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration.~400 mg orally, twice daily"

OTHER

Placebo

"Placebo contains no active ingredients.~465 mg pure olive oil orally, twice daily"

Trial Locations (2)

33612

Moffitt Cancer Center, Tampa

68198-6880

University of Nebraska Medical Center, Omaha

All Listed Sponsors
collaborator

American River Nutrition, LLC

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT06519097 - Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3) | Biotech Hunter | Biotech Hunter